Journal of Shandong University (Health Sciences) ›› 2025, Vol. 63 ›› Issue (12): 44-52.doi: 10.6040/j.issn.1671-7554.0.2024.1248

• Clinical Medicine • Previous Articles    

Relationship between gut microbiota and pancreatic cancer in East Asians: genetic evidence based on Mendelian randomization

DU Kaihao1, HOU Lizhao2, DONG Xiaoge1, XUE Weiwei1, HE Jiejie1, LUO Lanminghui1, JIANG Wei1, WANG Zhanjin1, WANG Zhan2,3   

  1. 1. Qinghai University Clinical Medical College, Xining 810016, Qinghai, China;;
    2. Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Qinghai University, Xining 810001, Qinghai, China;;
    3. Department of Medical Engineering Integration and Translational Application, Affiliated Hospital of Qinghai University, Xining 810001, Qinghai, China)
  • Published:2025-12-19

PDF (PC)

11

Abstract: Objective To explore the causal relationship between gut microbiota(GM)and pancreatic cancer(PC)in East Asians to reveal the potential pathological mechanisms of PC and provide a theoretical basis for clinical interventions. Methods Mendelian randomization(MR)analysis was conducted using data from genome-wide association studies(GWAS)databases to analyze the relationships between 500 gut microbiota features and PC in East Asians. Single nucleotide polymorphisms were used as instrumental variables, and various MR methods, including inverse variance weighting(IVW), weighted median method, and Bayesian weighted MR, were employed to assess the causal relationship between GM and PC. Results The results of the inverse-variance weighted method showed that g_Eremococcus ［Biobank Japan(BBJ): OR=0.847, 95%CI: 0.734-0.978, P=0.024; European Bioinformatics Institute(EBI): OR=0.829, 95%CI: 0.727-0.945, P=0.005), s_Acinetobacter_baumannii(BBJ: OR=0.775, 95%CI: 0.667-0.900, P=0.001; EBI: OR=0.828, 95%CI: 0.731-0.937, P=0.003), methionine metabolism I(MF0038)(BBJ: OR=0.299, 95%CI: 0.097-0.917, P=0.035; EBI: OR=0.260, 95%CI: 0.110-0.615, P=0.002), and g_Helicobacter(BBJ: OR=0.771, 95%CI: 0.657-0.905, P=0.001; EBI: OR=0.807, 95%CI: 0.700-0.930, P=0.003)were associated with a reduced risk of PC, whereas s_Prevotella_amnii(BBJ: OR=1.328, 95%CI: 1.086-1.623, P=0.006; EBI: OR=1.258, 95%CI: 1.041-1.520, P=0.018), s_Bacteroides_salanitronis(BBJ: OR=1.473, 95%CI: 1.150-1.887, P=0.002; EBI: OR=1.242, 95%CI: 1.030-1.497, P=0.023), and g_Acidovorax(BBJ: OR=1.184, 95%CI: 1.021-1.374, P=0.026; EBI: OR=1.166, 95%CI: 1.015-1.339, P=0.030)were associated with an increased risk of PC, and the results of the Bayesian weighted MR method similarly showed that g_Eremococcus(BBJ: OR=0.844, 95%CI: 0.725-0.983, P=0.029; EBI: OR=0.825, 95%CI: 0.717-0.949, P=0.007), s_Acinetobacter_baumannii(BBJ: OR=0.766, 95%CI: 0.647-0.906, P=0.002; EBI: OR=0.823, 95%CI: 0.720-0.939, P=0.004), methionine metabolism I(MF0038)(BBJ: OR=0.270, 95%CI: 0.082-0.888, P=0.031; EBI: OR=0.245, 95%CI: 0.098-0.610, P=0.003), and g_Helicobacter(BBJ: OR=0.768, 95%CI: 0.647-0.912, P=0.003; EBI: OR=0.802, 95%CI: 0.689-0.934, P=0.004)were associated with a reduced risk of PC, while s_Prevotella_amnii(BBJ: OR=1.340, 95%CI: 1.076-1.668, P=0.009; EBI: OR=1.262, 95%CI: 1.030-1.547, P=0.025), s_Bacteroides_salanitronis(BBJ: OR=1.487, 95%CI: 1.145-1.931, P=0.003; EBI: OR=1.256, 95%CI: 1.031-1.531, P=0.024), and g_Acidovorax(BBJ: OR=1.189, 95%CI: 1.017-1.390, P=0.029; EBI: OR=1.170, 95%CI: 1.011-1.353, P=0.036)were associated with an increased risk of PC. Sensitivity analyses suggested that the results were robust. Conclusion g_Eremococcus, s_Acinetobacter_baumannii, methionine metabolism pathway I(MF0038), and g_Helicobacter may serve as protective factors for PC, while s_Prevotella_amnii, s_Bacteroides_salanitronis, and g_Acidovorax may increase the risk of PC.

Key words: Gut microbiota, Pancreatic cancer, Mendelian randomization, Genome-wide association study, Single nucleotide polymorphisms

CLC Number: 

  • R735.9
[1] Zhan ZW, Zheng XH, Xu SH, et al. Rising burden of pancreatic cancer in China: trends, drivers, and future projections[J]. PLoS One, 2025, 20(7): e0327009. doi: 10.1371/journal.pone.0327009
[2] He Y, Zhou XL, Fan XQ, et al. Disease burden of pancreatic cancer - China, 1990-2019[J]. China CDC Wkly, 2022, 4(24): 527.
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4] 国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5): 1006-1030. General Office of National Health Commission. Standard for diagnosis and treatment of pancreatic cancer(2022 edition)[J]. Journal of Clinical Hepatology, 2022, 38(5): 1006-1030.
[5] Kolbeinsson HM, Chandana S, Wright GP, et al. Panc-reatic cancer: a review of current treatment and novel therapies[J]. J Invest Surg, 2023, 36(1): 2129884. doi: 10.1080/08941939.2022.2129884
[6] Tong Y, Gao HR, Qi QC, et al. High fat diet, gut microbiome and gastrointestinal cancer[J]. Theranostics, 2021, 11(12): 5889-5910.
[7] Cohen LJ, Cho JH, Gevers D, et al. Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases[J]. Gastroenterology, 2019, 156(8): 2174-2189.
[8] Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(11): 690-704.
[9] Yang QY, Zhang JH, Zhu Y. Potential roles of the gut microbiota in pancreatic carcinogenesis and therapeutics[J]. Front Cell Infect Microbiol, 2022, 12: 872019. doi: 10.3389/fcimb.2022.872019
[10] Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response[J]. Gastroenterology, 2018, 155(1): 33-37.
[11] Yu Q, Newsome RC, Beveridge M, et al. Intestinal microbiota modulates pancreatic carcinogenesis through intratumoral natural killer cells[J]. Gut Microbes, 2022, 14(1): 2112881. doi: 10.1080/19490976.2022.2112881
[12] Papa V, Schepis T, Coppola G, et al. The role of microbiota in pancreatic cancer[J]. Cancers(Basel), 2023, 15(12): 3143. doi: 10.3390/cancers15123143
[13] Jiang H, Song TJ, Li ZY, et al. Dissecting the association between gut microbiota and liver cancer in European and East Asian populations using Mendelian randomization analysis[J]. Front Microbiol, 2023, 14: 1255650. doi: 10.3389/fmicb.2023.1255650
[14] Yadav D, Ghosh TS, Mande SS. Global investigation of composition and interaction networks in gut microbiomes of individuals belonging to diverse geographies and age-groups[J]. Gut Pathog, 2016, 8: 17. doi: 10.1186/s13099-016-0099-z
[15] Syromyatnikov M, Nesterova E, Gladkikh M, et al. Characteristics of the gut bacterial composition in people of different nationalities and religions[J]. Microorga-nisms, 2022, 10(9): 1866. doi: 10.3390/microorganisms10091866
[16] 吴彤, 杨晶玉, 林盪, 等. 基于孟德尔随机化方法探讨脂质和降脂药物与慢性阻塞性肺病的遗传关联[J]. 山东大学学报(医学版), 2024, 62(5): 54-63. WU Tong, YANG Jingyu, LIN Dang, et al. Genetic association of lipids and lipid-lowering drugs with chronic obstructive pulmonary disease based on Mendelian randomization[J]. Journal of Shandong University(Health Sciences), 2024, 62(5): 54-63.
[17] Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods[J]. Stat Med, 2016, 35(11): 1880-1906.
[18] 柴红强, 庞磊, 吴明, 等. 利用两样本孟德尔随机化方法探究茶摄入量与膀胱癌发病风险的因果关系[J]. 现代肿瘤医学, 2023, 31(18): 3450-3454. CHAI Hongqiang, PANG Lei, WU Ming, et al. Using two sample Mendelian randomization method to explore the causal relationship between tea intake and the risk of bladder cancer[J]. Journal of Modern Oncology, 2023, 31(18): 3450-3454.
[19] Liu XM, Tong X, Zou YQ, et al. Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome[J]. Nat Genet, 2022, 54(1): 52-61.
[20] 张展, 李建锋, 李燕玲, 等. 饮食因素与子痫前期因果关系的孟德尔随机化分析[J]. 山东大学学报(医学版), 2024, 62(8): 59-66. ZHANG Zhan, LI Jianfeng, LI Yanling, et al. Mendelian randomization analysis of causality between dietary factors and preeclampsia[J]. Journal of Shandong University(Health Sciences), 2024, 62(8): 59-66.
[21] 吴飞, 李清丽, 肖振卫. 孟德尔随机化探究细胞因子与慢性肾脏病的因果关系[J]. 山东大学学报(医学版), 2024, 62(11): 85-95. WU Fei, LI Qingli, XIAO Zhenwei. Causal association between cytokines and chronic kidney disease based on Mendelian randomization[J]. Journal of Shandong University(Health Sciences), 2024, 62(11): 85-95.
[22] 冯悦, 俞一凡, 吴思佳, 等. 内脏脂肪组织与肺部疾病的孟德尔随机化研究[J]. 山东大学学报(医学版), 2024, 62(7): 48-55. FENG Yue, YU Yifan, WU Sijia, et al. Mendelian randomization study of visceral adipose tissue and lung diseases[J]. Journal of Shandong University(Health Sciences), 2024, 62(7): 48-55.
[23] Wang CD, Zhu DD, Zhang DJ, et al. Causal role of immune cells in schizophrenia: Mendelian randomization(MR)study[J]. BMC Psychiatry, 2023, 23(1): 590. doi: 10.1186/s12888-023-05081-4
[24] Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants[J]. Int J Epidemiol, 2011, 40(3): 740-752.
[25] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression[J]. Int J Epidemiol, 2015, 44(2): 512-525.
[26] Zhao J, Ming JS, Hu XH, et al. Bayesian weighted Mendelian randomization for causal inference based on summary statistics[J]. Bioinformatics, 2020, 36(5): 1501-1508.
[27] Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4): 439-457.
[28] Seo MS, Yeo J, Hwang IC, et al. Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis[J]. Clin Rheumatol, 2019, 38(11): 3109-3116.
[29] Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50(5): 693-698.
[30] Wu FS, Huang Y, Hu JL, et al. Mendelian randomization study of inflammatory bowel disease and bone mineral density[J]. BMC Med, 2020, 18(1): 312. doi: 10.1186/s12916-020-01778-5
[31] Dong Y, Hu AQ, Han BX, et al. Mendelian randomization analysis reveals causal effects of blood lipidome on gestational diabetes mellitus[J]. Cardiovasc Diabetol, 2024, 23(1): 335. doi: 10.1186/s12933-024-02429-2
[32] Zhang TL, Cao YN, Zhao JQ, et al. Assessing the causal effect of genetically predicted metabolites and metabolic pathways on stroke[J]. J Transl Med, 2023, 21(1): 822. doi: 10.1186/s12967-023-04677-4
[33] Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement[J]. JAMA, 2021, 326(16): 1614-1621.
[34] Ertz-Archambault N, Keim P, Von Hoff D. Microbiome and pancreatic cancer: a comprehensive topic review of literature[J]. World J Gastroenterol, 2017, 23(10): 1899-1908.
[35] Hong JZ, Fu YF, Chen XQ, et al. Gut microbiome changes associated with chronic pancreatitis and pancreatic cancer: a systematic review and meta-analysis[J]. Int J Surg, 2024, 110(9): 5781-5794.
[36] Dickson I. Microbiome promotes pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 328. doi: 10.1038/s41575-018-0013-x
[37] Attebury H, Daley D. The gut microbiome and pancreatic cancer development and treatment[J]. Cancer J, 2023, 29(2): 49-56.
[38] Zhou CF, Xu XJ. Causal relationship between gut microbiota and pancreatic cancer: a two-sample Mendelian randomisation study[J]. Ann Pancreat Cancer, 2024, 7: 1. doi: 10.21037/apc-23-15
[39] Zhang ZL, Zhang H, Chen T, et al. Regulatory role of short-chain fatty acids in inflammatory bowel disease[J]. Cell Commun Signal, 2022, 20(1): 64. doi: 10.1186/s12964-022-00869-5
[40] Liu HY, Lu HD, Wang YX, et al. Unlocking the power of short-chain fatty acids in ameliorating intestinal mucosal immunity: a new porcine nutritional approach[J]. Front Cell Infect Microbiol, 2024, 14: 1449030. doi: 10.3389/fcimb.2024.1449030
[41] Li QX, Jin M, Liu YH, et al. Gut microbiota: its potential roles in pancreatic cancer[J]. Front Cell Infect Microbiol, 2020, 10: 572492. doi: 10.3389/fcimb.2020.572492
[42] Raderer M, Wrba F, Kornek G, et al. Association between Helicobacter pylori infection and pancreatic cancer[J]. Oncology, 1998, 55(1): 16-19.
[43] Kosunen TU, Pukkala E, Sarna S, et al. Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: a cohort study[J]. Int J Cancer, 2011, 128(2): 433-439.
[44] 窦逾常, 王江滨. 胰腺癌患者幽门螺杆菌感染的检测及临床意义[J]. 吉林大学学报(医学版), 2008, 34(2): 317-319. DOU Yuchang, WANG Jiangbin. Detection of H. pylori infection in patients with pancreatic cancer and clinical significance[J]. Journal of Jilin University(Medicine Edition), 2008, 34(2): 317-319.
[45] Lindkvist B, Johansen D, Borgström A, et al. A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer[J]. BMC Cancer, 2008, 8: 321. doi: 10.1186/1471-2407-8-321
[46] Rundle A, Ahsan H, Vineis P. Better cancer biomarker discovery through better study design[J]. Eur J Clin Invest, 2012, 42(12): 1350-1359.
[47] Risch HA, Lu LG, Kidd MS, et al. Helicobacter pylori seropositivities and risk of pancreatic carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(1): 172-178.
[48] Wang Y, Zhang FC, Wang YJ. Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2, 049 cases and 2, 861 controls[J]. Asian Pac J Cancer Prev, 2014, 15(11): 4449-4454.
[49] Wong-Rolle A, Wei HK, Zhao C, et al. Unexpected guests in the tumor microenvironment: microbiome in cancer[J]. Protein Cell, 2021, 12(5): 426-435.
[50] Gao F, Yu B, Rao BC, et al. The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment[J]. Front Immunol, 2022, 13: 1051987.
[51] Tabrizi E, Pourteymour Fard Tabrizi F, Mahmoud Khaled G, et al. Unraveling the gut microbiomes contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives[J]. Front Immunol, 2024, 15: 1434771.
[52] Marino A, Augello E, Stracquadanio S, et al. Unveiling the secrets of Acinetobacter baumannii: resistance, current treatments, and future innovations[J]. Int J Mol Sci, 2024, 25(13): 6814. doi: 10.3390/ijms25136814
[53] Shi JC, Cheng JH, Liu SR, et al. Acinetobacter baumannii: an evolving and cunning opponent[J]. Front Microbiol, 2024, 15: 1332108. doi: 10.3389/fmicb.2024.1332108
[54] Mohamed EA, Raafat MM, Samir Mohamed R, et al. Acinetobacter baumannii biofilm and its potential therapeutic targets[J]. Future J Pharm Sci, 2023, 9(1): 82. doi: 10.1186/s43094-023-00525-w
[55] Jeffreys S, Chambers JP, Yu JJ, et al. Insights into Acinetobacter baumannii protective immunity[J]. Front Immunol, 2022, 13: 1070424. doi: 10.3389/fimmu.2022.1070424
[56] Sanderson SM, Gao X, Dai ZW, et al. Methionine metabolism in health and cancer: a nexus of diet and precision medicine[J]. Nat Rev Cancer, 2019, 19(11): 625-637.
[57] Gao X, Sanderson SM, Dai ZW, et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism[J]. Nature, 2019, 572(7769): 397-401.
[58] Richie JP Jr, Sinha R, Dong Z, et al. Dietary methionine and total sulfur amino acid restriction in healthy adults[J]. J Nutr Health Aging, 2023, 27(2): 111-123.
[1] WANG Le, LUO Qingxin, WU Sijia, WU Yutong, GE Yilei, YU Yifan, WEI Yun, JI Hanbing, LIU Tiemei, ZHANG Ziyan, XIU Jiawei, XUE Fuzhong, LI Hongkai. Associations between frailty and the risk of epilepsy: a prospective cohort study and Mendelian randomization analysis [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 20-30.
[2] ZHU Yongcai, XIE Yan, QI Qiuchen, LI Peilong, WANG Chuanxin, DU Lutao. Value of a combined model based on ATM gene methylation of peripheral blood mononuclear cells in the early diagnosis of pancreatic cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 78-88.
[3] HUANG Xin, WANG Mengxue, FU Shufan, ZHANG Qiyue, XU Li. Causal association of metabolic syndrome and its components with digestive system malignancies: a two-sample Mendelian randomized study [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 86-94.
[4] WANG Xiaolei, FANG Jun, WANG An, ZHU Wuhui, SHI Guangjun. Two-sample Mendelian randomization of the relationship between gut microbiota and the risk of extrahepatic cholangiocarcinoma [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 44-50.
[5] LI Jianfeng, ZHANG Zhan, DING Xinhua, GAO Fentang, HE Qinli, XIE Ping. Mendelian randomization analysis of dietary factors and cognitive impairment in European populations [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 36-43.
[6] XU Jingjing, WANG Xinqi, ZHANG Yang, XU Wangwang, GAO Jin. Effects of P2X7 receptor inhibitors on behaviour and gut microbiota in adolescent rats with post-traumatic stress disorder [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 1-9.
[7] YANG Hui, SU Shijing, LI Fen. Study on the causal relationship between cathepsins and risk of frailty based on bidirectional two-sample Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 67-76.
[8] CHANG Yu, HU Yunfeng, WANG Huifeng, GUO Jing, ZHANG Tiao, HAO Yaqin, LIU Yu. A mendelian randomization study on the association between appendectomy and the risk of colorectal cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 77-83.
[9] YANG Huimin, GONG Wanli, HOU Yaqi, WU Jing, WANG Yang, HE Peifeng, YU Qi. Causal association between 20 amino acids and coronary heart disease: a Mendelian randomization study [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 6-16.
[10] YANG Chuntao, ZUO Yu. Causal relationship of MMP1 and MMP9 genes with chronic periodontitis: an exploratory study based on two-sample Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 87-97.
[11] ZHOU Kun, LIU Ting, JIANG Yanju, HU Zekai, LI Yujia, FENG Wuyi, HUANG Jili, YE Wangquan, ZHAO Xiaofeng, HU Jun. Mendelian randomization analysis of the causal association between pain and muscle strength in knee osteoarthritis [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 61-67.
[12] YUAN Zonghuai, PAN Guangye, CHI Yuemei, AN Chuanguo, ZHANG Yonggang. Causal relationship between low grade serous ovarian cancer and breast cancer analyzed by Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 99-107.
[13] ZHANG Zhan, LI Jianfeng, LI Yanling, WANG Bowen, ANGWEN Chenglinlongzhu, WANG Xin, ZHANG Xiaoming, XIE Ping. Mendelian randomization analysis of causality between dietary factors and preeclampsia [J]. Journal of Shandong University (Health Sciences), 2024, 62(8): 59-66.
[14] LIU Shaoting, ZHANG Weiwei, RAN Qian, WANG Jian. Dietary emulsifiers and intestinal health [J]. Journal of Shandong University (Health Sciences), 2024, 62(8): 18-26.
[15] FENG Yue, YU Yifan, WU Sijia, LI Hongkai, XUE Fuzhong. Mendelian randomization study of visceral adipose tissue and lung diseases [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 48-55.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd